Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. News
  7. Summary
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biocartis Group NV Launches Idylla™ SARS-CoV-2/Flu/RSV Panel

09/02/2021 | 01:00am EDT

Biocartis Group NV announced the launch of its Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD). Building upon the success of its Idylla™ SARS-CoV-2 Test (CE-IVD), the new Panel is launching as a CE-IVD and detects, in one single cartridge, SARS-CoV-2, Flu A/B and RSV1 nucleic acids, with results in approx. 90 minutes. The Idylla™ SARS-CoV-2/Flu/RSV Panel is a fully automated rRT-PCR2 test intended for the qualitative detection of SARS-CoV-2, Flu A/B and RSV nucleic acids in nasopharyngeal swab specimens from individuals suspected of respiratory infections by their healthcare provider. The nasopharyngeal swab specimens are collected in a viral transport medium3 and can be pipetted directly into the cartridge. The Idylla™ SARS-CoV-2/Flu/RSV Panel includes fully automated nucleic acid testing with the extraction, amplification and detection in a single-use cartridge, with less than 1 minute hands-on time. The Panel showed excellent performance in the clinical performance study with 98% overall concordance compared with other currently used methods.


© S&P Capital IQ 2021
All news about BIOCARTIS GROUP NV
10/12BIOCARTIS : Disclosure of a transparency notification
PU
10/12PRESS NEWS BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
09/23BIOCARTIS : Restarts Production Of ML2 Manufacturing Line
MT
09/23BIOCARTIS : Announces Restart of its High-Throughput Cartridge Manufacturing Line
PU
09/23PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Restart of its High-Throughput Cart..
AQ
09/23Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Lin..
CI
09/13BIOCARTIS : Disclosure of a transparency notification
PU
09/13PRESS RELEASE BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
09/02BIOCARTIS : Webcast presentation H1 2021 results
PU
09/02BIOCARTIS : announces H1 2021 results
PU
More news
Financials
Sales 2021 52,9 M 61,7 M 61,7 M
Net income 2021 -81,0 M -94,5 M -94,5 M
Net Debt 2021 106 M 124 M 124 M
P/E ratio 2021 -3,06x
Yield 2021 -
Capitalization 234 M 272 M 273 M
EV / Sales 2021 6,43x
EV / Sales 2022 5,33x
Nbr of Employees 484
Free-Float 86,4%
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,07 €
Average target price 6,50 €
Spread / Average Target 59,7%
EPS Revisions
Managers and Directors
Herman Verrelst Chief Executive Officer & Executive Director
Jean-Marc Roelandt Chief Financial Officer
Christian Reinaudo Independent Chairman
Benoit Devogelaere Chief Technology Officer
Piet Houwen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCARTIS GROUP NV-12.47%272
MASIMO CORPORATION5.58%15 600
GETINGE AB113.07%12 994
NOVOCURE LIMITED-30.22%12 486
PENUMBRA, INC.59.43%10 206
SHOCKWAVE MEDICAL, INC.104.97%7 473